3 active not recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
Follow Recurrent Cervical Carcinoma: new trials by email Literature Review of Recurrent Cervical Carcinoma trials Research Report on Recurrent Cervical Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dostarlimab and Cobolimab in Advanced Cervical Cancer Dostarlimab, Cobolimab - Cervical Cancer, Advanced Cervical Carcinoma | Phase 2 | Active not recruiting | Meghan Shea | 66 | 2024-03-11 | 2026-01-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Laboratory Biomarker Analysis, Nivolumab - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 26 | 2015-05-18 | 2026-10-22 |
Uterine Cervical Neoplasms (3) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1) · Melanoma (1) · Multiple Myeloma (1) · Ovarian Neoplasms (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Neoplasms (3) · Neoplasms by Site (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Uterine Cervical Diseases (3) · Uterine Diseases (3) · Uterine Neoplasms (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Blood Protein Disorders (1)
Nivolumab (2) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1) · Biopsy (1) · CT-P6 (1) · Crizotinib (1) · Dasatinib (1) · Disulfides (1) · GSK2636771 (1) · HhAntag691 (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1)
National Cancer Institute (NCI) (2) · Meghan Shea (1)
United States (3) · Guam (1) · Puerto Rico (1)
Alessandro D Santin (1) · Keith T Flaherty (1) · Meghan Shea, MD (1)
PMID 26586415, PMID 31924334, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729
U10CA180820 (1), U10CA180868 (1), U24CA196172 (1)